UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
|
| ||
|
| |||||
(State or other Jurisdiction of Incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) | ||
|
|
| ||||
| ||||||
(Address of Principal Executive Offices) |
| (Zip Code) | ||||
Registrant’s telephone number, including area code: (
|
Not Applicable |
(Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
The (Nasdaq Global Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
On November 2, 2022, J. Philip Jones resigned as Chief Financial Officer of Alimera Sciences, Inc. (the “Company”), effective November 28, 2022. In his role as Chief Financial Officer, Mr. Jones has served as the Company’s principal financial officer and principal accounting officer. His resignation is not the result of any dispute or disagreement with the Company, the Company’s management, or the Company’s board of directors on any matter relating to the operations, policies or practices of the Company.
The Company has begun a search for a replacement Chief Financial Officer.
The Company thanks Mr. Jones for his service as CFO since January 2019 and for his contributions to the Company since June 2015 and wishes him the best in his future endeavors.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
|
|
Exhibit No. |
| Description |
104 |
| Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
| ALIMERA SCIENCES, INC. | |
|
| |
Dated: November 4, 2022 | By: | /s/ Richard S. Eiswirth, Jr. |
| Name: | Richard S. Eiswirth, Jr. |
| Title: | President and Chief Executive Officer |
Document and Entity Information |
Nov. 02, 2022 |
|---|---|
| Document and Entity Information [Abstract] | |
| Document Type | 8-K |
| Document Period End Date | Nov. 02, 2022 |
| Entity Registrant Name | ALIMERA SCIENCES, INC. |
| Entity Incorporation, State or Country Code | DE |
| Entity File Number | 001-34703 |
| Entity Tax Identification Number | 20-0028718 |
| Entity Address, Address Line One | 6310 Town Square |
| Entity Address, Address Line Two | Suite 400 |
| Entity Address, City or Town | Alpharetta |
| Entity Address, State or Province | GA |
| Entity Address, Postal Zip Code | 30005 |
| City Area Code | 678 |
| Local Phone Number | 990-5740 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, $0.01 par value per share |
| Trading Symbol | ALIM |
| Security Exchange Name | NASDAQ |
| Emerging Growth Company | false |
| Entity Central Index Key | 0001267602 |
| Amendment Flag | false |